BioMedPartners closes new venture capital fund
Basel-based venture capitalist firm BioMedPartners has closed its new venture capital fund BioMedInvest III at 100 million Swiss francs. The fund will help drive growth in the Swiss life science cluster by investing in private early-to-mid-stage companies.
Main investors in the BioMedInvest III healthcare venture capital fund are the European Investment Fund (EIF) and the Berner Kantonalbank (BEKB). According to Markus Hosang, General Partner at BioMedPartners, his company also succeeded in gaining the Basellandschaftliche Kantonalbank (BLKB) and several important individuals as new investors.
“We are proud of having established BioMedPartners as a leading venture group and early-stage life science investor in Europe over the last 15 years since its inception,” added Thomas Möller, General Partner at BioMedPartners. “The successful closing of our third equity venture fund is also a major milestone for the future growth of the Life Science Cluster in Switzerland.”
The Basel-based company will invest 100 million Swiss francs in 12 to 15 biopharmaceutical, medical device and diagnostics companies. It will also take an active role in these companies by providing its expertise and access to its network of industry experts and scientific leaders.
The fund’s focus is on Swiss companies as well as those from neighbouring countries. For instance, its first three investments are: Allecra Therapeutics, a French antibiotics company based in the Basel area, Amal Therapeutics in Geneva, and the German biotech company Cardior Pharmaceuticals.
Share this article
You might also be interested in
The Basel-based pharmaceutical supplier Lonza is supporting the US firm Humanigen in the development of a potential coronavirus therapeutic. Lonza...Read More
Startups from the Basel Area have been ranked highly in the TOP 100 Swiss Startup Award by Venturelab. The medtech...Read More
The U.S. Food and Drug Administration has given the Basel-based life sciences company Roche authorization to use a test that...Read More
The Chinese life sciences company Hengrui Medicine is establishing a Swiss subsidiary in Basel. The European hub for clinical research...Read More
The Basel Area-based company Polyphor has signed an exclusive licensing agreement with Fosun Pharma in China. Fosun Pharma will lead...Read More
With the new “swiss hosting” label, the Basel-based company swiss made software Gmbh is guaranteeing that data will not be...Read More
Karin Crisanto recently joined Basel Area Business & Innovation as Head of Innovation Space and Infrastructure. She previously worked for...Read More